1.
Brown JR, Ghia P, Jurczak W, Kahl BS, Lamanna N, Robak T, Shadman M, Tam CS, Qiu L, Paik J, Salmi T, Wang L, Zhang J, Zhang M, Cohen A, Ma H, Tedeschi A. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: <i>post-hoc</i&gt; analysis of a large clinical trial safety database. Haematologica 2024;109(7):2277-2283; https://doi.org/10.3324/haematol.2023.283846.